Renu Therapeutics

Renu is developing novel proteins to treat ischemic injury. Our lead program, Intestinal Trefoil Factor (ITF), is a secreted protein with a known role in mucosal repair. Renu has shown that acute admin of recombinant ITF significantly reduces myocardial infarct size in a mouse model. Renu is developing recombinant human ITF for acute post-MI therapy with potential to protect the ischemic myocardium from injury and minimize cardiomyocyte death, ultimately improving outcomes for AMI patients.